Protalix BioTherapeutics, Inc. has appointed Dror Bashan as president and chief executive officer, and director, effective June 30, 2019.  He succeeds Moshe Manor, who is stepping down but will assist with the transition and continue to work with the company as a consultant.

Mr. Bashan has more than 20 years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance providing him with cross regional and experience and knowledge of the global pharmaceutical and health industries. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd.  Most recently, he served as Teva’s senior vice president, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets.

“Dror brings valuable experience and knowledge in the pharmaceutical industry to our Company, and I am happy to welcome him to Protalix,” said Shlomo Yanai, chairman of Protalix’s Board of Directors. “Moshe has made a great contribution to our organization over the last four years, and has played a critical role in our development and success in advancing our pipeline.  On behalf of Protalix and the Board of Directors, I would like to thank Moshe for his significant contributions and outstanding leadership and wish him great success in his future endeavors.”

“I have the deepest gratitude to Protalix’s employees and its Board of Directors.  I have decided that, for personal reasons unrelated to the Company, the time has come to hand over leadership to a new chief executive officer,” said Mr. Manor.  “I am very honored to have led this great organization and will continue to watch with excitement and anticipation as Protalix progresses in the development and commercialization of its promising pipeline.”